Shares of Edwards Lifesciences (NYSE:EW) lost nearly 7 percent today, after a Centers for Medicare & Medicaid decision to review its coverage policy for a type of replacement heart valve.
CMS said it plans to go over "evidence pertaining to the health outcomes attributable to the use of [transcatheter aortic valve replacement], including evidence on the experience and qualifications of physicians and facilities that affect these outcomes."